Bruce Eaton has served as the President and Chief Executive Officer of Velocity Sciences since its founding in 2014. Dr. Bruce Eaton has been involved in commercial Bioscience endeavors in Colorado and California for over 30 years in both therapeutics and human diagnostics leading to two successful IPO’s. Dr. Eaton has to date founded four companies in the U.S. focused on pharmaceuticals, diagnostics and agrochemicals. In addition to serving as President and CEO of Velocity Sciences, Dr. Eaton serves as Chairman and Chief Executive Officer of i2 Pharmaceuticals. He is currently a member of the Board of Directors of the Colorado Bioscience Association and the Colorado Institute for Drug Device and Diagnostic Development. As Vice President of Chemistry at NeXstar Pharmaceuticals he directed the efforts of more than 50 scientists including the group responsible for the production of the first successful aptamer IND, NX1838 now known as Macugen™ (Eyetech Pharmaceuticals), marketed by Pfizer for age-related macular degeneration. Leading this chemistry effort, he was responsible for the acquisition and operation of chemistry companies in both the US and Europe. Dr. Bruce Eaton is an accomplished innovator with more than 70 patents issued worldwide. He has published several landmark articles in top-tier peer reviewed journals and given technical lectures around the world. Dr. Eaton received his Ph.D. degree in Chemistry in 1988 from the University of California at Berkeley.